Mice deficient in protein tyrosine phosphatase receptor type Z (PTPRZ) show reduced responsivity to methamphetamine despite an enhanced response to novelty.
Animals
Behavior, Animal
/ drug effects
Central Nervous System Stimulants
/ pharmacology
Dopamine
/ metabolism
Dopamine Plasma Membrane Transport Proteins
/ metabolism
Dopaminergic Neurons
/ drug effects
Exploratory Behavior
Locomotion
/ drug effects
Male
Methamphetamine
/ pharmacology
Mice
Mice, Knockout
Models, Animal
Receptor-Like Protein Tyrosine Phosphatases, Class 5
/ genetics
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
25
01
2019
accepted:
02
08
2019
entrez:
21
8
2019
pubmed:
21
8
2019
medline:
3
4
2020
Statut:
epublish
Résumé
Methamphetamine (METH), a commonly abused drug, elevates extracellular dopamine (DA) levels by inducing DA efflux through the DA transporter (DAT). Emerging evidence in rodent models suggests that locomotor responses to a novel inescapable open field may predict behavioral responses to abused drugs; METH produces more potent stimulant effects in high responders to novelty than in low responders. We herein found that mice deficient in protein tyrosine phosphatase receptor type Z (Ptprz-KO) exhibited an enhanced behavioral response to novelty; however, METH-induced hyperlocomotion was significantly lower in Ptprz-KO than in wild-type mice when METH was administered at a non-toxic dose of 1 mg per kg body weight (bdw). Single-cell RT-PCR revealed that the majority of midbrain DA neurons expressed PTPRZ. No histological alterations were observed in the mesolimbic or nigrostriatal dopaminergic pathways in Ptprz-KO brains; however, a significant decrease was noted in brain DA turnover, suggesting functional alterations. In vivo microdialysis experiments revealed that METH-evoked DA release in the nucleus accumbens was significantly lower in Ptprz-KO mice than in wild-type mice. Consistent with this result, Ptprz-KO mice showed significantly fewer cell surface DAT as well as weaker DA uptake activity in striatal synaptosomes prepared 1 hr after the administration of METH than wild-type mice, while no significant differences were observed in the two groups treated with saline. These results indicate that the high response phenotype of Ptprz-KO mice to novelty may not be simply attributed to hyper-dopaminergic activity, and that deficits in PTPRZ reduce the effects of METH by reducing DAT activity.
Identifiants
pubmed: 31430310
doi: 10.1371/journal.pone.0221205
pii: PONE-D-19-02378
pmc: PMC6701799
doi:
Substances chimiques
Central Nervous System Stimulants
0
Dopamine Plasma Membrane Transport Proteins
0
Methamphetamine
44RAL3456C
Ptprz1 protein, mouse
EC 3.1.3.48
Receptor-Like Protein Tyrosine Phosphatases, Class 5
EC 3.1.3.48
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0221205Déclaration de conflit d'intérêts
SHIONOGI & CO. LTD provided support in the form of salary for author GS. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Mol Cell Biol. 2000 Oct;20(20):7706-15
pubmed: 11003666
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1982-7
pubmed: 11172062
Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6593-8
pubmed: 11381105
Hippocampus. 2001;11(5):551-68
pubmed: 11732708
Nat Genet. 2003 Mar;33(3):375-81
pubmed: 12598897
Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7417-21
pubmed: 1323835
Pharmacol Biochem Behav. 2004 Sep;79(1):65-74
pubmed: 15388285
Methods. 2005 Jan;35(1):54-63
pubmed: 15588986
J Neurosci. 2005 Feb 2;25(5):1081-8
pubmed: 15689543
Neuron. 2005 Jun 2;46(5):703-13
pubmed: 15924857
Prog Neurobiol. 2005 Apr;75(6):406-33
pubmed: 15955613
Neurosci Lett. 2006 May 15;399(1-2):33-8
pubmed: 16513268
Handb Exp Pharmacol. 2006;(175):197-214
pubmed: 16722237
Biol Psychiatry. 2007 Apr 1;61(7):890-901
pubmed: 17046726
J Neurochem. 2007 May;101(4):883-8
pubmed: 17250674
Pharmacol Biochem Behav. 2007 May;87(1):158-63
pubmed: 17524461
J Biochem. 2007 Sep;142(3):343-50
pubmed: 17646177
Neurosci Lett. 2008 Sep 19;442(3):208-12
pubmed: 18647637
J Biol Chem. 2008 Nov 7;283(45):30879-89
pubmed: 18713734
J Neurosci. 2009 Sep 16;29(37):11628-40
pubmed: 19759310
Ann N Y Acad Sci. 2010 Feb;1187:218-46
pubmed: 20201856
J Biochem. 2011 Jun;149(6):641-53
pubmed: 21508038
J Biol Chem. 2011 Oct 28;286(43):37137-46
pubmed: 21890632
Trends Neurosci. 2011 Dec;34(12):629-37
pubmed: 22051158
PLoS One. 2012;7(11):e48797
pubmed: 23144976
PLoS One. 2015 Mar 05;10(3):e0119361
pubmed: 25742295
Nat Neurosci. 2015 Aug;18(8):1084-93
pubmed: 26147533
Science. 1989 Sep 29;245(4925):1511-3
pubmed: 2781295
J Biochem. 2017 Nov 1;162(5):381-390
pubmed: 28992190
Glia. 2019 May;67(5):967-984
pubmed: 30667096
PLoS One. 2019 Jun 13;14(6):e0217880
pubmed: 31194769
Physiol Behav. 1988;42(4):371-7
pubmed: 3387491
J Neurochem. 1966 Aug;13(8):655-69
pubmed: 5950056
Psychopharmacology (Berl). 1984;84(2):167-73
pubmed: 6438676
FEBS Lett. 1994 Oct 31;354(1):67-70
pubmed: 7957903
Behav Brain Res. 1996 May;77(1-2):23-43
pubmed: 8762157
Biochem Biophys Res Commun. 1997 Jan 13;230(2):419-25
pubmed: 9016795
Neurosci Lett. 1997 Mar 21;224(3):201-5
pubmed: 9131671
J Pharmacol Exp Ther. 1997 Aug;282(2):834-8
pubmed: 9262348
Brain Res Dev Brain Res. 1998 May 15;107(2):219-26
pubmed: 9593903
Neurosci Lett. 1998 May 15;247(2-3):135-8
pubmed: 9655611
Brain Res. 1998 Sep 21;806(1):1-7
pubmed: 9739098
Neuropharmacology. 1998 Sep;37(9):1177-84
pubmed: 9833648